- Policy
- Verquvo will be listed for reimb at KRW 2,867 in KOR
- by Kim, Jung-Ju Aug 24, 2023 05:46am
- The 3 doses of Bayer Korea’s chronic heart failure treatment Verquvo Tab will be newly listed at KRW 2,867. The price of Abbott Korea’s Depakote Sprinkle Cap (divalproex sodium) will be raised by nearly 22% upon the company’s request and negotiations. According to industry sources on the 22nd, the Ministry of Health and Welfare is worki
- Policy
- Generics for Januvia are deleted from the reimbursement list
- by Lee, Tak-Sun Aug 24, 2023 05:46am
- 6 While 239 drugs containing Sitagliptin, the active ingredient of DPP-4 diabetes treatment Januvia, will be registered for benefit on the 2nd of next month, six existing supplementary items will be deleted from the benefits list. It is interpreted that five items were excluded from the medical care benefit due to the newly created negotiatio
- Company
- Will the new NMOSD drug Enspryng be reimbursed in KOR?
- by Eo, Yun-Ho Aug 24, 2023 05:46am
- Whether the new drug for neuromyelitis optica spectrum disorder (NMOSD) can be reimbursed in Kore is gaining attention. Dailypharm found that Roche Korea is carrying out pricing negotiations with the National Health Insurance Service for the reimbursement of its NMOSD treatment Ensprying (satralizumab). The drug passed the Health Insur
- Policy
- Conflict rise over the need of the PE exemption system
- by Lee, Jeong-Hwan Aug 24, 2023 05:45am
- Experts are showing a sharp conflict of opinion over the effectiveness and need for the existence of Korea's system that exempts new drugs from receiving pharmacoeconomic evaluations. The PE exemption system, which was introduced in 2015, was implemented to improve access to new drugs for patients with severe and rare diseases. However,
- Company
- The report distorted the side effects of JW Pharma Hemlibra
- by Kim, Jin-Gu Aug 23, 2023 05:46am
- Rather, JW Pharma's official position is that the total number of adverse events, including thromboembolism, is more than three times greater in factor VIII. JW Pharma issued a statement on the 22nd and refuted the press release distributed by GC Pharma the previous day (21st). GC Pharma participated in the Bleeding Disorders Conference and d
- Policy
- 157 single and 82 combo Januvia generics reimbursed in KOR
- by Lee, Tak-Sun Aug 23, 2023 05:46am
- TA total of 239 new drugs that contain ‘sitagliptin,’ the active ingredient of the DPP-4 inhibitor class drug Januvia (MSD), will pour out onto the market on the 2nd of next month. In terms of the number of companies, 59 companies will be releasing their single-agent generics and 63 will be releasing their fixed-combination generics.
- Policy
- 'No other country has a PE exemption system'
- by Lee, Jeong-Hwan Aug 23, 2023 05:46am
- “Korea is the only country that has introduced the use of the pharmacoeconomic evaluation exemption system. As an academic, I do not understand the logic of the PE exemption system. It is also difficult to explain to other countries. If a particular drug has received reimbursement at a non-cost effective price due to the system, it will con
- Policy
- Envlomet SR is priced at 611 won, the same price as Envlo
- by Lee, Tak-Sun Aug 23, 2023 05:46am
- Daewoong Pharmaceutical's self-developed SGLT2i ingredient, Enavogliflozin, combined with Metformin hydrochloride will be released in September. In particular, even though metformin hydrochloride is added, the price is the same as the existing single drug Envlo. This is related to the drug price calculation structure for combination drugs. Ac
- Company
- FST measure remains the issue for Luxturna's reimb
- by Eo, Yun-Ho Aug 23, 2023 05:46am
- Whether the differences in opinion over the ‘performance-based standard’ that has risen as an issue during reimbursement discussions for the one-shot retinal dystrophy treatment ‘Luxturna’ will be reconciled is gaining attention. Dailypharm found that the full-field sensitivity threshold (FST) has been set as the standard for evaluati
- Company
- What to do with the loss of drug price cuts?
- by Chon, Seung-Hyun Aug 22, 2023 05:31am
- Pharmaceutical companies are in deep trouble ahead of the end of generic drug price re-evaluation. As each pharmaceutical company announces drug price cuts for as many as 100 or more products, the atmosphere is concentrating on figuring out the size of the loss. Dissatisfaction with the government's indiscriminate re-evaluation of drug price
